High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma
Open accessThe DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
BACKGROUND: High-dose therapy with supporting autologous stem-cell transplantation remains a controversial treatment for cancer. In multiple myeloma, first-line regimens incorporating high-dose therapy yield higher remission rates than do conventional-dose treatments, but evidence that this translates into improved survival is limited. METHODS: In this multicenter study, the Medical Research Council Myeloma VII Trial, we randomly assigned 407 patients with previously untreated multiple myeloma who were younger than 65 years of age to receive either standard conventional-dose combination chemotherapy or high-dose therapy and an autologous stem-cell transplant. RESULTS: Among the 401 patients who could be evaluated, the rates of complete response were higher in the intensive-therapy group than in the standard-therapy group (44 percent vs. 8 percent, P<0.001). The rates of partial response were similar (42 percent and 40 percent, respectively; P=0.72), and the rates of minimal response were lower in the intensive-therapy group than in the standard-therapy group (3 percent vs. 18 percent, P<0.001). Intention-to-treat analysis showed a higher rate of overall survival (P=0.04 by the log-rank test) and progression-free survival (P<0.001) in the intensive-therapy group than in the standard-therapy group. As compared with standard therapy, intensive treatment increased median survival by almost 1 year (54.1 months [95 percent confidence interval, 44.9 to 65.2] vs. 42.3 months [95 percent confidence interval, 33.1 to 51.6]). There was a trend toward a greater survival benefit in the group of patients with a poor prognosis, as defined by a high beta2-microglobulin level (more than 8 mg per liter). CONCLUSIONS: High-dose therapy with autologous stem-cell rescue is an effective first-line treatment for patients with multiple myeloma who are younger than 65 years of age.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“ASCT improves median OS in multiple myeloma by approximately 12 months.125–128”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [126]
Citations
Cites
Attal, M., Harousseau, J.-L., Stoppa, A.-M., Sotto, J.-J., Fuzibet, J.-G., Rossi, J.-F., Casassus, P., Maisonneuve, H., Facon, T., Ifrah, N., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199607113350204 · Cited by 2,548
Ttal, M. I. A., Ean, J., Dünne, A. A., Toppa, A. S., Ossi, R. G., Hilippe, P., Asassus, C., Acon, T. H. F., Orbert, N., Ayen, C. A. P., et al. (2013) · Cited by 2,161
BladÉ, J., Samson, D., Reece, D., Apperley, J., BJÖrkstrand, B., Gahrton, G., Gertz, M., Giralt, S., Jagannath, S., Vesole, D., et al. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00930.x · Cited by 1,519
Fermand, J.-P., Ravaud, P., Chevret, S., Divine, M., Leblond, V., Belanger, C., Macro, M., Pertuiset, E., Dreyfus, F., Mariette, X., et al. (1998) · Blood · doi:10.1182/blood.v92.9.3131 · Cited by 542
Barlogie, B., Jagannath, S., Vesole, D. H., Naucke, S., Cheson, B., Mattox, S., Bracy, D., Salmon, S., Jacobson, J., Crowley, J., et al. (1997) · Blood · doi:10.1182/blood.v89.3.789 · Cited by 541
HIGH-DOSE INTRAVENOUS MELPHALAN FOR PLASMA-CELL LEUKAEMIA AND MYELOMA
MCELWAIN, T. (1983) · The Lancet · doi:10.1016/s0140-6736(83)90739-0 · Cited by 510
Total Therapy With Tandem Transplants for Newly Diagnosed Multiple Myeloma
Barlogie, B., Jagannath, S., Desikan, K. R., Mattox, S., Vesole, D., Siegel, D., Tricot, G., Munshi, N., Fassas, A., Singhal, S., et al. (1999) · Blood · doi:10.1182/blood.v93.1.55.401k04_55_65 · Cited by 502
Total Therapy With Tandem Transplants for Newly Diagnosed Multiple Myeloma
Barlogie, B., Jagannath, S., Desikan, K. R., Mattox, S., Vesole, D., Siegel, D., Tricot, G., Munshi, N., Fassas, A., Singhal, S., et al. (1999) · Blood · doi:10.1182/blood.v93.1.55 · Cited by 472
Facon, T., Avet-Loiseau, H., Guillerm, G., Moreau, P., Geneviève, F., Zandecki, M., Laı̈, J.-L., Leleu, X., Jouet, J.-P., Bauters, F., et al. (2001) · Blood · doi:10.1182/blood.v97.6.1566 · Cited by 312
Lenhoff, S., Hjorth, M., Holmberg, E. C., Turesson, I., Westin, J., Nielsen, J. L., Wislöff, F., Brinch, L., Carlson, K. E., Carlsson, M. S., et al. (2000) · PubMed · doi:10.1182/blood.v95.1.7 · Cited by 310
Research works printed but not linked: 7
- Morgan G, Selby P. Myeloma. In: Souhami R, Tannock I, Hohenberger P, Horiot J-C, eds. Oxford textbook of oncology. 2nd ed. Vol. 2. Oxford, England: Oxford University Press, 2001:2419-55.
- Lenhoff S, 2000, Blood, 95, 7
- Fermand J-P, 1999, Blood, 94, 396a
- Review manager (RevMan), version 4.1. Oxford, England: Cochrane Collaboration, 2000.
- Blade J, 2001, Blood, 98, 815a
- Segeren CM, 2001, Blood, 98, 815a
- Fermand J-P, 2001, Blood, 98, 815a
Cited by
Items 701–800 of 1,000
Orciuolo, E., Buda, G., Marturano, E., Mauro, E., Milone, G., Cangialosi, C., Renzo, N. D., Pastore, D., Specchia, G., Paolis, M. R. D., et al. (2010) · Leukemia Research · doi:10.1016/j.leukres.2010.10.029 · Cited by 22
“[2] Child JA, Morgan GJ, Davies FE, Owen RG, Bell SE, Hawkins K, et al.”
BackgroundImmunotherapy of multiple myeloma: the start of a long and tortuous journey
Harrison, S. J., Cook, G., Nibbs, R. J. B., & Prince, H. M. (2006) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.6.12.1769 · Cited by 22
Martino, M. V., Olivieri, A., Offidani, M., Vigna, E., Moscato, T., Fedele, R., Montanari, M., Console, G., Gentile, M., Messina, G., et al. (2013) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2013.788643 · Cited by 23
“(auto-HPCT) has represented a milestone in the treatment of MM and Phase III trials [9-14] have demonstrated that this treatment strategy results in improved clinical responses, compared with conventional chemotherapy (CC) [15].”
BackgroundResultPancreatic Involvement by Plasma Cell Neoplasms
da Silva, R. L. (2011) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-011-9314-9 · Cited by 30
Douglas, K., Parker, A. N., Hayden, P. J., Rahemtulla, A., D’Addio, A., Lemoli, R. M., Rao, K. V., Maris, M. B., Pagliuca, A., Uberti, J. P., et al. (2011) · Bone Marrow Transplantation · doi:10.1038/bmt.2011.9 · Cited by 22
Stem cell transplantation for multiple myeloma
Kumar, S. K. (2009) · Current Opinion in Oncology · doi:10.1097/cco.0b013e328324bc04 · Cited by 25
Martino, M. V., Montanari, M., Bruno, B., Console, G., Irrera, G., Messina, G., Offidani, M., Scortechini, I., Moscato, T., Fedele, R., et al. (2012) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2012.707185 · Cited by 22
“diagnosed MM [10,11], based on the increased rate of complete response (CR), prolonged disease free (DFS) and overall survival (OS), compared with conventional chemotherapy (CC) in several randomized studies [12,13].”
Nieto, Y. L., Valdez, B. C., Pingali, S. R., Bassett, R. L., Delgado, R., Nguyen, J., Shah, N. D., Popat, U., Jones, R. B., Andersson, B. S., et al. (2017) · The Lancet Haematology · doi:10.1016/s2352-3026(17)30080-7 · Cited by 22
The challenges of checkpoint inhibition in the treatment of multiple myeloma
Paul, B. A., Kang, S., Zheng, Z., & Kang, Y. (2018) · Cellular Immunology · doi:10.1016/j.cellimm.2018.10.003 · Cited by 24
The outcome of unrelated donor stem cell transplantation for patients with multiple myeloma
Shaw, B. E., Peggs, K. S., Bird, J. M., Cavenagh, J. D., Hunter, A., Madrigal, J. A., Russell, N. H., Sirohi, B., Towlson, K. E., Williams, C. D., et al. (2003) · British Journal of Haematology · doi:10.1046/j.1365-2141.2003.04714.x · Cited by 22
“Young patients with myeloma, who may be candidates for UD-SCT, have mainly received high dose melphalan and autologous SCTs, but this does not offer them a prospect of cure (Attal & Harousseau, 1997; Child et al, 2003).”
BackgroundHematopoietic Stem Cell Transplantation in Multiple Myeloma
Pant, S., & Copelan, E. A. (2007) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2007.05.002 · Cited by 22
Samaras, P., Pfrommer, S., Seifert, B., Petrausch, U., Mischo, A., Schmidt, A., Schanz, U., Nair, G., Bargetzi, M. J., Taverna, C., et al. (2014) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2014.09.020 · Cited by 21
Melphalan: old and new uses of a still master drug for multiple myeloma
Musto, P., & D’Auria, F. (2007) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.16.9.1467 · Cited by 21
“This more important tumor burden reduction could be converted into a statistically significant prolongation of EFS and OS by 12 – 18 months in some of the published studies so far comparing ASCT with conventional CT [62] and, in particular, in randomized trials with long-term follow up, where treatment-related mortali…”
ResultBalint, B., Ljubenov, M., Stamatović, D., Todorović, M., Pavlović, M. D., Ostojic, G., Jocić, M., & Trkuljić, M. (2008) · Vojnosanitetski pregled · doi:10.2298/vsp0807545b · Cited by 21
Cost of Treatment of Multiple Myeloma in a Public Sector Tertiary Care Hospital of North India
Kaur, G., Prinja, S., Malhotra, P., Lad, D. P., Prakash, G., Khadwal, A., Ramachandran, R., & Varma, S. C. (2017) · Indian Journal of Hematology and Blood Transfusion · doi:10.1007/s12288-017-0843-7 · Cited by 21
Costa, L. J., Landau, H. J., Chhabra, S., Hari, P., Innis-Shelton, R. D., Godby, K. N., Hamadani, M., Tamari, R., Anderton, K., Dixon, P. M., et al. (2018) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2018.01.036 · Cited by 21
Paquin, A. R., Visram, A., Kumar, S. K., Gertz, M. A., Cantwell, H., Buadi, F. K., Lacy, M. Q., Dispenzieri, A. A., Dingli, D., Hwa, Y. L., et al. (2020) · Blood Cancer Journal · doi:10.1038/s41408-020-00353-8 · Cited by 22
Gupta, S., Zhou, P. H., Hassoun, H., Kewalramani, T., REICH, L. M., Costello, S., Drake, L., Klimek, V. M., Dhodapkar, M. V., Teruya‐Feldstein, J., et al. (2005) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1704779 · Cited by 21
Does stem cell transplantation have a role in the management of multiple myeloma, 2009?
Gertz, M. A., & Buadi, F. K. (2008) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560802636839 · Cited by 21
“Stem cell transplantation was shown in two key prospective randomized studies to be superior to conventional chemotherapy resulting in both improved event-free and overall survival [1,2] .”
BackgroundCancer Stem Cells: From Bench to Bedside
Jones, R. J., & Matsui, W. H. (2007) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2006.10.010 · Cited by 21
Iacobelli, S., de Wreede, L. C., Schönland, S. O., Björkstrand, B., Hegenbart, U., Gruber, A., Greinix, H., Volin, L., Narni, F., Carella, A. M., et al. (2015) · Bone Marrow Transplantation · doi:10.1038/bmt.2014.310 · Cited by 21
Reményi, P., Varga, G., Mikala, G., Réti, M., Gopcsa, L., Bátai, Á., Csukly, Z., Lengyel, L., Torbágyi, É., Barta, A., et al. (2016) · Transplantation Proceedings · doi:10.1016/j.transproceed.2015.12.031 · Cited by 21
Lum, L. G., Thakur, A. B., Kondadasula, S. V., Al-Kadhimi, Z. S., Deol, A., Tomaszewski, E. N., Yano, H., Schalk, D. L., Ayash, L. J., Zonder, J. A., et al. (2016) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2015.12.030 · Cited by 21
“Although high-dose chemotherapy (HDC) followed by autologous stem cell transplantation (SCT) can induce complete responses in patients with multiple myeloma (MM), there are no curative therapies [1-10].”
BackgroundAutologous Hematopoietic Cell Transplantation in Patients With Multiple Myeloma: Effect of Age
Dhakal, B., Nelson, A. A., Murthy, G. S. G., Fraser, R. A., Eastwood, D. C., Hamadani, M., Pasquini, M. C., D’Souza, A., & Hari, P. (2016) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2016.11.006 · Cited by 22
BU and CY as conditioning regimen for autologous transplant in patients with multiple myeloma
Talamo, G., Claxton, D. F., Dougherty, D. W., Ehmann, C. W., Sivik, J. M., Drabick, J. J., & Rybka, W. B. (2009) · Bone Marrow Transplantation · doi:10.1038/bmt.2008.446 · Cited by 22
Wang, S., Nademanee, A. P., Qian, D., Dagis, A., Park, H., Fridey, J. L., Smith, E., Snyder, D., Somlo, G., Stein, A. S., et al. (2007) · Transfusion · doi:10.1111/j.1537-2995.2007.01448.x · Cited by 21
A Case of Atypical Light Chain Deposition Disease—Diagnosis and Treatment
Salant, D. J., Sanchorawala, V., & D’Agati, V. D. (2007) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.00970207 · Cited by 21
“Recently, the use of myeloablative doses of melphalan combined with autologous stem cell transplantation (HDM/SCT), as has been used to treat multiple myeloma (29,30) and systemic AL amyloidosis (2), has been described for patients with both heavy and light chain deposition diseases (1,31,32).”
Bortezomib Treatment for Multiple Myeloma
Stanford, B. L., & Zondor, S. D. (2003) · Annals of Pharmacotherapy · doi:10.1345/aph.1d262 · Cited by 22
Gertz, M. A., Lacy, M. Q., Dispenzieri, A. A., Hayman, S. R., & Kumar, S. K. (2006) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.6.3.343 · Cited by 24
Therapeutic approaches for newly diagnosed multiple myeloma patients in the era of novel drugs
Morabito, F., Gentile, M., Mazzone, C., Bringhen, S., Vigna, E., Lucia, E., Recchia, A. G., Raimondo, F. D., Musto, P., & Palumbo, A. (2010) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2010.01472.x · Cited by 20
“In the 1990s, randomized trials demonstrating that autologous stem cell transplantation (ASCT) prolongs survival compared to conventional chemotherapy led to the incorporation of ASCT into the MM treatment strategy in younger patients (32, 33).”
BackgroundPianko, M. J., & Golob, J. L. (2022) · Cancer and Metastasis Reviews · doi:10.1007/s10555-022-10033-7 · Cited by 23
Minimal residual disease testing after stem cell transplantation for multiple myeloma
Sherrod, A. M., Hari, P., Mosse, C. A., Walker, R., & Cornell, R. F. (2015) · Bone Marrow Transplantation · doi:10.1038/bmt.2015.164 · Cited by 23
Veeraputhiran, M. K., Jain, T., Deol, A., Ayash, L. J., Kim, S., Dyson, G. E., Bhutani, D., Lum, L. G., Ratanatharathorn, V., Uberti, J. P., et al. (2015) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2015.05.008 · Cited by 20
Wang, M., Delasalle, K. B., Giralt, S., & Alexanian, R. (2010) · Hematology · doi:10.1179/102453310x12583347010133 · Cited by 23
Gagliardi, F., Boari, N., & Mortini, P. (2013) · Neurosurgical Review · doi:10.1007/s10143-013-0463-0 · Cited by 20
High-Dose Melphalan and the Development of Hematopoietic Stem-Cell Transplantation: 25 Years Later
Lazarus, H. M., Phillips, G. L., Herzig, R. H., Hurd, D. D., Wolff, S. N., & Herzig, G. P. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7827 · Cited by 20
Inhibition of Nek2 by Small Molecules Affects Proteasome Activity
Meng, L., Carpenter, K. J., Mollard, A., Vankayalapati, H., Warner, S. L., Sharma, S., Tricot, G. J. K., Zhan, F., & Bearss, D. J. (2014) · BioMed Research International · doi:10.1155/2014/273180 · Cited by 21
Long-term survival after surgical intervention for bone disease in multiple myeloma
Zeifang, F., Zahlten‐Hinguranage, A., Goldschmidt, H., Cremer, F. W., Bernd, L., & Sabo, D. (2005) · Annals of Oncology · doi:10.1093/annonc/mdi054 · Cited by 20
“Owing to a change in methodology from CC followed by HDT with PBSCT, a considerable improvement in overall survival could be achieved for patients with newly diagnosed MM [5].”
BackgroundMethodBiran, N., Jacobus, S. J., Vesole, D. H., Callander, N. S., Fonseca, R., Williams, M. E., Abonour, R., Katz, M. S., Rajkumar, S. V., Greipp, P. R., et al. (2016) · Blood Cancer Journal · doi:10.1038/bcj.2016.68 · Cited by 23
On behalf of the Swiss Blood Stem Cell Transplantation Registry, Ghilardi, G., Pabst, T., Jeker, B., Müller, R., Cairoli, A., Müller, A. M. S., Bargetzi, M. J., Hitz, F., Baldomero, H., et al. (2018) · Bone Marrow Transplantation · doi:10.1038/s41409-018-0379-y · Cited by 21
Sidiqi, M. H., Aljama, M. A., Riaz, I. B., Dispenzieri, A. A., Muchtar, E., Buadi, F. K., Warsame, R. M., Lacy, M. Q., Dingli, D., Leung, N., et al. (2018) · Blood Cancer Journal · doi:10.1038/s41408-018-0147-7 · Cited by 21
Derman, B. A., Zha, Y., Zimmerman, T. M., Malloy, R., Jakubowiak, A. J., Bishop, M. R., & Kline, J. P. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000286 · Cited by 20
Bal, S., Landau, H. J., Shah, G. L., Scordo, M., Dahi, P. B., Lahoud, O. B., Hassoun, H., Hultcrantz, M. L., Korde, N., Lendvai, N. K., et al. (2020) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2020.04.011 · Cited by 20
Bachier, C. R., Potter, J., Potter, G. W., Sugay, R., Shaughnessy, P. J., Chan, K., Jude, V. H., Madden, R. M., & LeMaistre, C. F. (2011) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2011.12.500 · Cited by 20
Morris, T. C. M., Velangi, M., Jackson, G. H., Marks, D. I., & Ranaghan, L. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.05340.x · Cited by 20
“…survey* Although there is now substantial evidence from randomized trials of the benefits of high-dose therapy supported by autologous transplantation in myeloma patients under 65 years of age (Attal et al, 1996; Child et al, 2003), the availability/uptake of this therapy is not known.”
BackgroundRosiñol, L., García‐Sánz, R., Lahuerta, J. J., Hernandez-Garcia, M., Granell, M., de la Rubia, J., Oriol, A., Hernández-Ruíz, B., Rayón, C., Navarro, I., et al. (2011) · Haematologica · doi:10.3324/haematol.2011.051441 · Cited by 20
Pharmacokinetic evaluation of pomalidomide for the treatment of myeloma
Gay, F., Mina, R., Troia, R., & Bringhen, S. (2013) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2013.827169 · Cited by 21
“Upfront treatment options for elderly patients and those not eligible for ASCT include the 3-drug regimen consisting of melphalan-prednisone (MP) plus thalidomide, or bortezomib and MPlenalidomide followed by lenalidomide maintenance, that showed increased PFS in comparison with the old standard MP,or a 2-drug combina…”
BackgroundInfluentialPalumbo, A., Bringhen, S., Falco, P., Cavallo, F., Ambrosini, M. T., Avonto, I., Gay, F., Caravita, T., Bruno, B., & Boccadoro, M. (2007) · Cancer · doi:10.1002/cncr.22855 · Cited by 20
Katragadda, L., McCullough, L. M., Dai, Y. E., Hsu, J. W., Byrne, M. T., Hiemenz, J., May, S. W., Cogle, C. R., Norkin, M., Brown, R. A., et al. (2016) · Clinical Transplantation · doi:10.1111/ctr.12762 · Cited by 22
“DurieSalmon stage I 8 (6) 2 (6) 6 (6) .”
Oyekunle, A. A., Shumilov, E., Kostrewa, P., Burchert, A., Trümper, L. H. P., Wuchter, P., Wulf, G. G., Bacher, U., & Kröger, N. M. (2017) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2017.10.008 · Cited by 20
Safety Outcomes for Autologous Stem Cell Transplant in Multiple Myeloma
Gertz, M. A., Buadi, F. K., Hayman, S. R., Lacy, M. Q., Dispenzieri, A. A., Dingli, D., Gonsalves, W. I., Kumar, S. K., Kapoor, P., Kourelis, T., et al. (2018) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2017.09.012 · Cited by 20
Sagaster, V., Kaufmann, H., Odelga, V., Ackermann, J., Gisslinger, H., Rabitsch, W., Zojer, N., Ludwig, H., Nösslinger, T., Zielinski, C. C., et al. (2006) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2006.00807.x · Cited by 20
“Due to the superiority of high-dose melphalan with autologous stem cell support over standard-dose chemotherapy (33, 34), treatment of young MM patients is quite different from that of elderly MM patients.”
BackgroundBuchmann, I., Meyer, R. G., Mier, W., & Haberkorn, U. (2009) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-008-0996-6 · Cited by 20
Hart, C. A., Grassinger, J., Andreesen, R., & Hennemann, B. (2008) · Bone Marrow Transplantation · doi:10.1038/bmt.2008.315 · Cited by 20
Five decades of therapy for multiple myeloma: a paradigm for therapeutic models
Kyle, R. A. (2005) · Leukemia · doi:10.1038/sj.leu.2403728 · Cited by 20
Cook, G., Clark, R. E., Morris, T. C. M., Robertson, M. D., Lucie, N. P., Anderson, S., Paul, J., & FRANKLIN, I. M. (2004) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.05127.x · Cited by 20
“However, the use of dose escalation therapy with or without autologous peripheral blood stem cell (PBSC) rescue after initial combination therapy has demonstrated improve survival (McElwain & Powles, 1983; Harousseau & Attal, 1997; Fermand et al, 1998; Child et al, 2003).”
BackgroundInfluentialAllogeneic stem cell transplantation in multiple myeloma: immunotherapy and new drugs
Festuccia, M. B., Martino, M. V., Ferrando, F., Messina, G., Moscato, T., Fedele, R., Boccadoro, M., Giaccone, L., & Bruno, B. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2015.1036735 · Cited by 20
“Despite the introduction of the so-called new drugs, single or double auto-SCT remains part of standard upfront treatment in patients up to the age of 65 [21-24], whereas the upfront use of RIC allo-SCT has practically been abandoned and remains to be undefined.”
Biran, N., Ely, S. A., & Chari, A. (2014) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-014-0237-y · Cited by 19
Grešlíková, H., Zaoralová, R., Filková, H., Němec, P., Oltová, A., Kupská, R., Rudolecka, P., Smetana, J., Pour, L., Zahradová, L., et al. (2010) · Neoplasma · doi:10.4149/neo_2010_02_111 · Cited by 19
Sheppard, D., Bredeson, C., Huebsch, L. B., Allan, D., & Tay, J. (2014) · Bone Marrow Transplantation · doi:10.1038/bmt.2014.33 · Cited by 19
Considerations in the treatment of multiple myeloma: a consensus statement from Italian experts
Patriarca, F. F., Petrucci, M. T., Bringhen, S., Baldini, L., Caravita, T., Corradini, P., Corso, A., Raimondo, F. D., Falcone, A. P., Ferrara, F., et al. (2008) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2008.01179.x · Cited by 21
Straka, C., Sandherr, M., Salwender, H. J., Wandt, H., Metzner, B., Hübel, K., Silling, G., Hentrich, M., Franke, D., Schwerdtfeger, R., et al. (2010) · Blood · doi:10.1182/blood-2010-06-290080 · Cited by 20
Augmenting Autologous Stem Cell Transplantation to Improve Outcomes in Myeloma
Maybury, B. D., Cook, G., Pratt, G., Yong, K., & Ramasamy, K. (2016) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2016.06.004 · Cited by 22
Sivaraj, D., Bacon, W., Long, G. D., Rizzieri, D. A., Horwitz, M. E., Sullivan, K. M., Kang, Y., Li, Z., Chao, N. J. A., & Gasparetto, C. (2017) · Bone Marrow Transplantation · doi:10.1038/bmt.2017.208 · Cited by 20
Huang, J. J., Phillips, S. E., Byrne, M. T., Chinratanalab, W., Engelhardt, B. G., Goodman, S. A., Harrell, S. L., Jagasia, M., Kassim, A. A., Rawling, K. T., et al. (2018) · Bone Marrow Transplantation · doi:10.1038/s41409-018-0177-6 · Cited by 19
Prediction and prognostic significance of BCAR3 expression in patients with multiple myeloma
Zhang, W., Lin, Y., Liu, X., He, X., Zhang, Y., Fu, W., Yang, Z., Yang, P., Wang, J., Hu, K., et al. (2018) · Journal of Translational Medicine · doi:10.1186/s12967-018-1728-8 · Cited by 22
“Discussion For MM patients with age less than 65 years, high-dose treatment with autologous stem cells is a first-line effective treatment [31].”
Terebelo, H. R., Abonour, R., Gasparetto, C., TOOMEY, K. E., Durie, B. G. M., Hardin, J. W., Jagannath, S., Wagner, L. I., Narang, M., Flick, E. D., et al. (2019) · British Journal of Haematology · doi:10.1111/bjh.16139 · Cited by 21
Lin, T., Wang, P., Kuo, M., Hung, Y., Chang, H., & Tang, T. (2015) · Journal of Clinical Apheresis · doi:10.1002/jca.21421 · Cited by 19
Imamura, M., Asano, S., Harada, M., Ikeda, Y., Kato, K., Kato, S., Kawa, K., Kojima, S., Morishima, Y., Morishita, Y., et al. (2006) · International Journal of Hematology · doi:10.1532/ijh97.05134 · Cited by 19
Wirk (2013) · Journal of Clinical Medicine Research · doi:10.4021/jocmr1274w · Cited by 19
“Standard therapy for multiple myeloma includes initial autologous hematopoietic cell transplantation (autoHCT1) which has been shown to improve the complete remission rate (CR), progression free survival (PFS) and overall survival (OS) compared to standard chemotherapy [1, 2].”
BackgroundMethodLenalidomide in multiple myeloma
Thomas, S. K., Richards, T. A., & Weber, D. M. (2007) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2007.09.002 · Cited by 19
Shin, J., Koh, Y., Youk, J., Kim, M., Kim, B. S., Choi, C. W., Sung, H. J., Park, Y., Yoon, S., & Kim, I. (2017) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2016.256 · Cited by 21
“High-dose therapy (HDT) followed by aHSCT has long been considered a standard treatment for MM patients younger than 65 years of age and shown to be superior to conventional combination chemotherapy in terms of response rate, PFS, and OS [18].”
BackgroundHigh-risk myeloma and minimal residual disease postautologous-HSCT predict worse outcomes
Hu, B., Thall, P. F., Milton, D. R., Sasaki, K., Bashir, Q., Shah, N. D., Patel, K. K., Popat, U., Hosing, C. M., Nieto, Y. L., et al. (2018) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2018.1485908 · Cited by 20
Cho, Y. K., Irby, D. J., Li, J., Sborov, D. W., Mould, D. R., Badawi, M. A., Dauki, A. M., Lamprecht, M., Rosko, A. E., Fernández, S., et al. (2018) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12345 · Cited by 19
“Autologous stem cell transplant (ASCT) is highly effective in patients with MM with ~40–55% achieving complete response with highdose chemotherapy.(2,3) Melphalan, a DNA alkylating agent, is given at a high, standard dose of 200 mg/m(2) in most patients as part of the conditioning regimen for ASCT in MM.”
BackgroundHematopoietic Stem Cell Transplantation
Im, A., & Pavletic, S. Z. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-47674-4.00028-1 · Cited by 19
Multiple Myeloma: Primary Bone Tumor with Systemic Manifestations
Bilsky, M. H., & Azeem, S. (2007) · Neurosurgery Clinics of North America · doi:10.1016/j.nec.2007.09.001 · Cited by 21
Meehan, K. R., Wu, J., Ernstoff, M. S., Webber, S. M., Barber, A., Szczepiorkowski, Z. M., & Sentman, C. L. (2008) · Cytotherapy · doi:10.1080/14653240701762398 · Cited by 19
Zheng, W., Wei, G., Ye, X., He, J., Li, L., Wu, W., Shi, J., Zhang, J., Huang, W., Xie, W., et al. (2009) · Leukemia Research · doi:10.1016/j.leukres.2009.04.006 · Cited by 19
“The intensive therapy, including igh-dose melphalan and autologous stem cell transplantation, engthens median survival from three years to five years [1–3].”
BackgroundChong, Y. P., Kim, S., Ko, O. B., Koo, J. E., Lee, D., Park, S. H., Park, S. J., Lee, D., Kim, S. W., & Suh, C. (2008) · Journal of Korean Medical Science · doi:10.3346/jkms.2008.23.5.819 · Cited by 19
“The overall response rate (CR and PR) following ASCT was 100% in the IgD MM group and 97% in patients with other MM subtypes, similar to that reported from other studies (9, 12, 13, 19).”
BackgroundResultRecent advances in the mangement of multiple myeloma.
Kumar, L., Vikram, P., & Kochupillai, V. (2006) · PubMed · Cited by 29
Jimenez-Zepeda, V. H., & Domínguez, V. J. (2006) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2006.00701.x · Cited by 21
Progress in hematopoietic stem cell transplantation in multiple myeloma
Gahrton, G. (2005) · Current Opinion in Hematology · doi:10.1097/01.moh.0000182836.40779.e7 · Cited by 19
Costa, B. A., Mouhieddine, T. H., Ortiz, R. J., & Richter, J. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.104040 · Cited by 18
How to treat a newly diagnosed young patient with multiple myeloma
Miguel, J. F. S., & Mateos, M. (2009) · Hematology · doi:10.1182/asheducation-2009.1.555 · Cited by 21
Alnasser, S. M., Alharbi, K. S., Almutairy, A. F., Almutairi, S. M., & Alolayan, A. M. (2023) · Cells · doi:10.3390/cells12242855 · Cited by 20
“However, they compared ASCT to SDC without transplantation based on clinical trials (Attal et al., 1996) (Child et al., 2003), with the conclusion that HDC followed by ASCT significantly increased PFS and OS compared to SDC [126,127].”
Hosing, C. M., Smith, V., Rhodes, B., Walters, K., Thompson, R., Qazilbash, M. H., Khouri, I. F., Lima, M. J. G. D., Balzer, R. J., McMannis, J. D., et al. (2011) · Transfusion · doi:10.1111/j.1537-2995.2011.03176.x · Cited by 18
Autologous Stem Cell Transplantation for Multiple Myeloma: Identification of Prognostic Factors
Kumar, L., Cyriac, S. L., Tilak, T., Bahl, A., Biswas, B., Sahoo, R. K., Mukherjee, A., & Sharma, O. D. (2012) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2012.08.007 · Cited by 18
Offidani, M., Leoni, P., Corvatta, L., Polloni, C., Gentili, S., Savini, A., Alesiani, F., Brunori, M., Catarini, M., Visani, G., et al. (2010) · European Journal Of Haematology · doi:10.1111/j.1600-0609.2010.01418.x · Cited by 18
Cellular and vaccine immunotherapy for multiple myeloma
Garfall, A. L., & Stadtmauer, E. A. (2016) · Hematology · doi:10.1182/asheducation-2016.1.521 · Cited by 20
Liu, Y., Han, H., Shah, G. L., Giralt, S., Landgren, O., He, J., & Lesokhin, A. M. (2018) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2018.08.030 · Cited by 18
Sweiss, K. I., Lee, J. W. J., Mahmud, N., Calip, G. S., Park, Y. M., Mahmud, D. L., Rondelli, D., & Patel, P. R. (2019) · Bone Marrow Transplantation · doi:10.1038/s41409-019-0681-3 · Cited by 19
Lemieux, C., Muffly, L. S., Rezvani, A. R., Lowsky, R., Iberri, D. J., Craig, J. K., Frank, M. J., Johnston, L., Liedtke, M., Negrin, R. S., et al. (2020) · Bone Marrow Transplantation · doi:10.1038/s41409-020-01026-7 · Cited by 19
Chemotherapy-based regimens in multiple myeloma in 2020
Gentile, M., Morabito, F., Martino, M. V., Vigna, E., Martino, E. A., Mendicino, F., Martinelli, G., & Cerchione, C. (2021) · Panminerva Medica · doi:10.23736/s0031-0808.20.04145-2 · Cited by 20
Tichopád, A., Vítová, V., Kořı́stek, Z., & Lysák, D. (2013) · Journal of Clinical Apheresis · doi:10.1002/jca.21290 · Cited by 18
Özkan, H. A., Bal, C., & Gülbaş, Z. (2013) · Transfusion and Apheresis Science · doi:10.1016/j.transci.2013.12.001 · Cited by 19
“Despite the development of new and effective agents, high-dose (HD) chemotherapy supported by autologous hematopoietic stem-cell transplantation (HSCT) remains an important treatment modality for the management of patients with plasma cell myeloma (PCM) and lymphoma (non-Hodgkin’s lymphoma and Hodgkin’s lymphoma) [1–…”
BackgroundOgawa, Y., Suzuki, K., Sakai, A., Iida, S., Ogura, M., Tobinai, K., Matsumoto, M., Matsue, K., Terui, Y., Ohashi, K., et al. (2013) · Cancer Science · doi:10.1111/cas.12172 · Cited by 18
Barlogie, B., Zangari, M., Bolejack, V., Hollmig, K. A., Anaissie, E. J., van Rhee, F., Pineda‐Roman, M., Mohiuddin, A., Crowley, J. J., & Tricot, G. J. K. (2006) · Clinical Lymphoma & Myeloma · doi:10.3816/clm.2006.n.027 · Cited by 19
Front-Line Treatment in Younger Patients With Multiple Myeloma
Rajkumar, S. V., & Sonneveld, P. (2009) · Seminars in Hematology · doi:10.1053/j.seminhematol.2009.02.005 · Cited by 18
“10 This model stratifies patients into high-risk and standard-risk myeloma based on detection of deletion 13 or hypodiploidy on meta-phase cytogenetic studies, deletion 17p- or immunoglobulin heavy chain (IgH) translocations t(4;14) or t(14;16) on molecular genetic studies, or plasma cell labeling index of 3% or highe…”
MethodStraka, C., Oduncu, F. S., Hinke, A., Einsele, H., Drexler, E., Schnabel, B., Arseniev, L., Walther, J., König, A., & Emmerich, B. (2004) · Blood · doi:10.1182/blood-2004-02-0628 · Cited by 18
“High-dose chemotherapy with autologous hematopoietic transplantation is the standard treatment in multiple myeloma today (Attal et al. 1996; Barlogie et al. 1997; Child et al. 2003).”
Raschle, J., Ratschiller, D., Mans, S., Mueller, B. U., & Pabst, T. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.329 · Cited by 18
“…stem cell transplantation is a cornerstone within the current standard treatment for symptomatic myeloma patients fit for intensive treatment (Child et al, 2003; Terpos et al, 2003; Barlogie et al, 2004; Blade et al, 2005; Fermand et al, 2005; Rajkumar and Kyle, 2005; Wang et al, 2007;…”
Background
Metadata
- Authors
- Child, J. A., Morgan, G. J., Davies, F. E., Owen, R. G., Bell, S. E., Hawkins, K., Brown, J., Drayson, M. T., & Selby, P. J.
- Affiliations
- University of Leeds (GB)
- University of Birmingham (GB)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2003-05-08
- Volume
- 348
- Issue
- 19
- Pages
- 1875-1883
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2102591890
- Semantic Scholar
- 5d90e1ff237e9db8f41e6e1e264450eed3f77e40
- Cited by
- 1,768
- References
- 23
- Citations by year
- 2026: 17 · 2025: 26 · 2024: 34 · 2023: 36 · 2022: 41 · 2021: 57 · 2020: 83 · 2019: 46 · 2018: 71 · 2017: 76 · 2016: 73 · 2015: 71 · 2014: 81 · 2013: 103 · 2012: 94
- FWCI
- 53.33
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
- Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
- Keywords
- multiple myeloma, high-dose chemotherapy, autologous stem cell transplantation, first-line therapy, complete response, overall survival, progression-free survival, beta2-microglobulin, prognostic factors, previously untreated myeloma
- MeSH terms
- Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, Carmustine, Cause of Death, Combined Modality Therapy, Cyclophosphamide, Doxorubicin, Female, Humans, Male, Melphalan, Middle Aged, Multiple Myeloma, Prognosis, Survival Analysis, Hematopoietic Stem Cell Transplantation, Antineoplastic Agents, Alkylating
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.